Sugi Predict

Sugi Predict / Compounds / SCHEMBL3220874

SCHEMBL3220874

SCHEMBL3220874

O=C(/C=C/C=C/c1ccc(O)cc1)/C=C/c1ccc(O)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYR P14679 3/20 0.80
▸ F3 P13726 3/20 0.80
▸ HSD11B1 P28845 2/20 0.80
▸ CYP2D6 P10635 2/20 0.80
▸ CYP2C9 P11712 2/20 0.80
▸ STAT3 P40763 1/20 0.76
▸ APP P05067 1/20 0.61
▸ GSK3B P49841 1/20 0.61
▸ BACE1 P56817 1/20 0.61
▸ TLR9 Q9NR96 1/20 0.61
▸ AKR1B10 O60218 2/20 0.59
▸ AKR1B1 P15121 2/20 0.59
▸ CA12 O43570 2/20 0.59
▸ CA1 P00915 2/20 0.59
▸ CA2 P00918 2/20 0.59
▸ CA7 P43166 2/20 0.59
▸ CA9 Q16790 2/20 0.59
▸ CA14 Q9ULX7 2/20 0.59
▸ PKM P14618 2/20 0.59
▸ ESR1 P03372 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3220877 1.00 TYR (0.80) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL3580956 0.89 TYR (1.00) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL2146080 0.89 TYR (1.00) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL2198475 0.89 TYR (1.00) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL4371653 0.87 TYR (0.95) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL10631270 0.87 TYR (0.95) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL4381938 0.87 TYR (0.95) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL4373677 0.87 TYR (0.95) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL4370894 0.87 TYR (0.95) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL23728340 0.85 STAT3 (0.58) TYRF3HSD11B1CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 — — US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 — — US claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 — — WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 — — WO claimed
US-20160354504-A1 MALODOR COUNTERACTING COMPOSITIONS INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2016-12-08 — — US claimed
EP-3101171-A1 MALODOR COUNTERACTING COMPOSITIONS International Flavors & Fragrances Inc. (US) 2016-12-07 — — EP claimed
US-20100048957-A1 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S H L 2010-02-25 — — US claimed
US-20250161394-A1 Compositions Comprising Kavalactones NATURAL EXTRACTION SYS LLC (US) 2025-05-22 — — US disclosed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 — — US disclosed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 — — US disclosed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 — — WO disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 — — WO disclosed
US-10912803-B2 Probiotic and polyphenol against neurodegeneration SOCIETE DES PRODUITS NESTLE S.A. (CH) 2021-02-09 — — US disclosed
US-7728043-B2 Methods for treatment of beta-amyloid protein-induced ocular disease KIM DARRICK S H L 2010-06-01 — — US disclosed
US-20100048957-A1 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S H L 2010-02-25 — — US disclosed
EP-2037762-A4 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S H L (US) 2009-07-08 — — EP disclosed
EP-2037762-A1 METHOD TO PREPARE PURE CURCUMIN Kim, Darrick S.H.L. (US) 2009-03-25 — — EP disclosed
WO-2007143635-A1 METHOD TO PREPARE PURE CURCUMIN KIM DARRICK S (US) 2007-12-13 — — WO disclosed
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease KIM DARRICK S H 2007-01-04 — — US disclosed
US-20060148905-A1 Methods for treatment of beta-amyloid protein-induced ocular disease KIM DARRICK S H 2006-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354504-A1 MALODOR COUNTERACTING COMPOSITIONS LPO, MAL2, ME1 TYR 17/4885F3 1552/4885HSD11B1 1161/4885
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB TYR 2156/4885F3 2718/4885HSD11B1 1640/4885
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease APP, BACE1, GSAP TYR 3707/4885F3 3129/4885HSD11B1 771/4885
US-20060148905-A1 Methods for treatment of beta-amyloid protein-induced ocular disease APP, CRYAB, BACE1 TYR 2123/4885F3 2347/4885HSD11B1 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.